{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:12:23Z","timestamp":1791645143461,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s42000-021-00282-6","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T10:02:58Z","timestamp":1617098578000},"page":"279-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Intravenous rituximab therapy for active Graves\u2019 ophthalmopathy: a meta-analysis"],"prefix":"10.1007","volume":"20","author":[{"given":"Jing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-2384","authenticated-orcid":false,"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"issue":"8","key":"282_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Graves\u2019 ophthalmopathy. N Engl J Med 362(8):726\u2013738. https:\/\/doi.org\/10.1056\/NEJMra0905750 [published Online First: 2010\/02\/26]","journal-title":"N Engl J Med"},{"issue":"6","key":"282_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/bf03346614","volume":"33","author":"TJ Smith","year":"2010","unstructured":"Smith TJ (2010) Pathogenesis of Graves\u2019 orbitopathy: a 2010 update. J Endocrinol Investig 33(6):414\u2013421. https:\/\/doi.org\/10.1007\/bf03346614 [published Online First: 2010\/07\/16]","journal-title":"J Endocrinol Investig"},{"issue":"10","key":"282_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMcp0806317","volume":"360","author":"L Bartalena","year":"2009","unstructured":"Bartalena L, Tanda ML (2009) Clinical practice. Graves\u2019 ophthalmopathy. N Engl J Med 360(10):994\u20131001. https:\/\/doi.org\/10.1056\/NEJMcp0806317 [published Online First: 2009\/03\/07]","journal-title":"N Engl J Med"},{"issue":"5","key":"282_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/phar.2111","volume":"38","author":"WC Shen","year":"2018","unstructured":"Shen WC, Lee CH, Loh EW et al (2018) Efficacy and safety of rituximab for the treatment of Graves\u2019 orbitopathy: a meta-analysis of randomized controlled trials. Pharmacotherapy 38(5):503\u2013510. https:\/\/doi.org\/10.1002\/phar.2111 [published Online First: 2018\/03\/31]","journal-title":"Pharmacotherapy"},{"issue":"5","key":"282_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/eje.0.1480491","volume":"148","author":"MF Prummel","year":"2003","unstructured":"Prummel MF, Bakker A, Wiersinga WM et al (2003) Multi-center study on the characteristics and treatment strategies of patients with Graves\u2019 orbitopathy: the first European Group on Graves\u2019 Orbitopathy experience. Eur J Endocrinol 148(5):491\u2013495. https:\/\/doi.org\/10.1530\/eje.0.1480491 [published Online First: 2003\/05\/02]","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"282_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320\u2013332. https:\/\/doi.org\/10.1210\/jc.2010-1962 [published Online First: 2011\/01\/18]","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"282_CR7","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G et al (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 90(9):5234\u20135240. https:\/\/doi.org\/10.1210\/jc.2005-0148 [published Online First: 2005\/07\/07]","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"282_CR8","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W et al (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab 97(12):4454\u20134463. https:\/\/doi.org\/10.1210\/jc.2012-2389 [published Online First: 2012\/10\/06]","journal-title":"J Clin Endocrinol Metab"},{"key":"282_CR9","doi-asserted-by":"publisher","unstructured":"Khong JJ, McNab A (2020) Medical treatment in thyroid eye disease in 2020. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316051 [published Online First: 2020\/05\/25]","DOI":"10.1136\/bjophthalmol-2020-316051"},{"issue":"3","key":"282_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.survophthal.2012.10.006","volume":"58","author":"S Shen","year":"2013","unstructured":"Shen S, Chan A, Sfikakis PP et al (2013) B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Surv Ophthalmol 58(3):252\u2013265. https:\/\/doi.org\/10.1016\/j.survophthal.2012.10.006 [published Online First: 2012\/12\/21]","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"282_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100(2):422\u2013431. https:\/\/doi.org\/10.1210\/jc.2014-3014 [published Online First: 2014\/12\/17]","journal-title":"J Clin Endocrinol Metab"},{"key":"282_CR12","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535 [published Online First: 2009\/07\/23]","journal-title":"BMJ"},{"issue":"1","key":"282_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M Salvi","year":"2007","unstructured":"Salvi M, Vannucchi G, Campi I et al (2007) Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156(1):33\u201340. https:\/\/doi.org\/10.1530\/eje.1.02325 [published Online First: 2007\/01\/16]","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"282_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","volume":"117","author":"D Khanna","year":"2010","unstructured":"Khanna D, Chong KK, Afifiyan NF et al (2010) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 117(1):133\u201339.e2. https:\/\/doi.org\/10.1016\/j.ophtha.2009.05.029 [published Online First: 2009\/10\/13]","journal-title":"Ophthalmology"},{"issue":"5","key":"282_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/IOP.0b013e3181c4dfde","volume":"26","author":"RZ Silkiss","year":"2010","unstructured":"Silkiss RZ, Reier A, Coleman M et al (2010) Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 26(5):310\u2013314. https:\/\/doi.org\/10.1097\/IOP.0b013e3181c4dfde [published Online First: 2010\/06\/22]","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"3","key":"282_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cen.12141","volume":"79","author":"AL Mitchell","year":"2013","unstructured":"Mitchell AL, Gan EH, Morris M et al (2013) The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy. Clin Endocrinol 79(3):437\u2013442. https:\/\/doi.org\/10.1111\/cen.12141 [published Online First: 2013\/01\/17]","journal-title":"Clin Endocrinol"},{"issue":"8","key":"282_CR17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3109\/08916934.2014.939266","volume":"47","author":"A Erdei","year":"2014","unstructured":"Erdei A, Paragh G, Kovacs P et al (2014) Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves\u2019 orbitopathy: a five-year follow-up study. Autoimmunity 47(8):548\u2013555. https:\/\/doi.org\/10.3109\/08916934.2014.939266 [published Online First: 2014\/07\/22]","journal-title":"Autoimmunity"},{"issue":"2","key":"282_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG et al (2015) Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab 100(2):432\u2013441. https:\/\/doi.org\/10.1210\/jc.2014-2572 [published Online First: 2014\/10\/25]","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"282_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.5603\/EP.a2017.0040","volume":"68","author":"D Karasek","year":"2017","unstructured":"Karasek D, Cibickova L, Karhanova M et al (2017) Clinical and immunological changes in patients with active moderate-to-severe Graves\u2019 orbitopathy treated with very low-dose rituximab. Endokrynol Pol 68(5):498\u2013504. https:\/\/doi.org\/10.5603\/EP.a2017.0040 [published Online First: 2017\/07\/01]","journal-title":"Endokrynol Pol"},{"issue":"1","key":"282_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/cen.13970","volume":"91","author":"EA Insull","year":"2019","unstructured":"Insull EA, Sipkova Z, David J et al (2019) Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment. Clin Endocrinol 91(1):179\u2013186. https:\/\/doi.org\/10.1111\/cen.13970 [published Online First: 2019\/03\/14]","journal-title":"Clin Endocrinol"},{"issue":"5","key":"282_CR21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/09273948.2018.1453078","volume":"27","author":"L Du Pasquier-Fediaevsky","year":"2019","unstructured":"Du Pasquier-Fediaevsky L, Andrei S, Berche M et al (2019) Low-dose rituximab for active moderate to severe Graves\u2019 orbitopathy resistant to conventional treatment. Ocul Immunol Inflamm 27(5):844\u2013850. https:\/\/doi.org\/10.1080\/09273948.2018.1453078 [published Online First: 2018\/04\/14]","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"282_CR22","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/1120672119845224","volume":"30","author":"L Eid","year":"2020","unstructured":"Eid L, Coste-Verdier V, Longueville E et al (2020) The effects of rituximab on Graves\u2019orbitopathy: a retrospective study of 14 patients. Eur J Ophthalmol 30(5):1008\u20131013. https:\/\/doi.org\/10.1177\/1120672119845224 [published Online First: 2019\/04\/27]","journal-title":"Eur J Ophthalmol"},{"issue":"9","key":"282_CR23","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00417-020-04651-6","volume":"258","author":"JB Deltour","year":"2020","unstructured":"Deltour JB, d\u2019Assigny Flamen M, Ladsous M et al (2020) Efficacy of rituximab in patients with Graves\u2019 orbitopathy: a retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol 258(9):2013\u20132021. https:\/\/doi.org\/10.1007\/s00417-020-04651-6 [published Online First: 2020\/05\/15]","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"282_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto KA, Merkesdal S, Hommel G et al (2013) Public health relevance of Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98(1):145\u2013152. https:\/\/doi.org\/10.1210\/jc.2012-3119 [published Online First: 2012\/11\/28]","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"282_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12886-018-0679-4","volume":"18","author":"C Wang","year":"2018","unstructured":"Wang C, Ning Q, Jin K et al (2018) Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis. BMC Ophthalmol 18(1):46. https:\/\/doi.org\/10.1186\/s12886-018-0679-4 [published Online First: 2018\/02\/18]","journal-title":"BMC Ophthalmol"},{"issue":"11","key":"282_CR26","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1210\/jc.2013-1804","volume":"98","author":"M Salvi","year":"2013","unstructured":"Salvi M, Vannucchi G, Beck-Peccoz P (2013) Potential utility of rituximab for Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98(11):4291\u20134299. https:\/\/doi.org\/10.1210\/jc.2013-1804 [published Online First: 2013\/09\/07]","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"282_CR27","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1530\/eje-16-0552","volume":"176","author":"MN Stan","year":"2017","unstructured":"Stan MN, Salvi M (2017) Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy - lessons from randomized control trials. Eur J Endocrinol 176(2):R101\u2013Rr09. https:\/\/doi.org\/10.1530\/eje-16-0552 [published Online First: 2016\/10\/21]","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"282_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","volume":"16","author":"PN Taylor","year":"2020","unstructured":"Taylor PN, Zhang L, Lee RWJ et al (2020) New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol 16(2):104\u2013116. https:\/\/doi.org\/10.1038\/s41574-019-0305-4 [published Online First: 2020\/01\/01]","journal-title":"Nat Rev Endocrinol"},{"key":"282_CR29","doi-asserted-by":"publisher","first-page":"7453260","DOI":"10.1155\/2019\/7453260","volume":"2019","author":"D Lacheta","year":"2019","unstructured":"Lacheta D, Miskiewicz P, Gluszko A et al (2019) Immunological aspects of Graves\u2019 ophthalmopathy. Biomed Res Int 2019:7453260. https:\/\/doi.org\/10.1155\/2019\/7453260 [published Online First: 2019\/11\/30]","journal-title":"Biomed Res Int"},{"key":"282_CR30","doi-asserted-by":"publisher","unstructured":"Li J, Xiao Z, Hu X et al (2017) The efficacy of rituximab combined with 131i for ophthalmic outcomes of Graves\u2019 ophthalmopathy patients. Pharmacology 99(3-4):144\u2013152. https:\/\/doi.org\/10.1159\/000453618 [published Online First: 2017\/01\/04]","DOI":"10.1159\/000453618"},{"issue":"2","key":"282_CR31","first-page":"173","volume":"38","author":"G Savino","year":"2013","unstructured":"Savino G, Balia L, Colucci D et al (2013) Intraorbital injection of rituximab: a new approach for active thyroid-associated orbitopathy, a prospective case series. Minerva endocrinol 38(2):173\u2013179 [published Online First: 2013\/06\/05]","journal-title":"Minerva endocrinol"},{"issue":"Suppl 1","key":"282_CR32","first-page":"1","volume":"62","author":"JR Wall","year":"2011","unstructured":"Wall JR, Lahooti H (2011) Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases? Endokrynol Pol 62(Suppl 1):1\u20137 [published Online First: 2012\/01\/10]","journal-title":"Endokrynol Pol"},{"key":"282_CR33","doi-asserted-by":"publisher","unstructured":"Mishra S, Maurya VK, Kumar S et al (2020) Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: current and future perspectives. Curr Eye Res:1\u201317. https:\/\/doi.org\/10.1080\/02713683.2020.1776331 [published Online First: 2020\/06\/23]","DOI":"10.1080\/02713683.2020.1776331"},{"issue":"5","key":"282_CR34","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1210\/jc.2013-4026","volume":"99","author":"T Diana","year":"2014","unstructured":"Diana T, Brown RS, Bossowski A et al (2014) Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves\u2019 disease-a multicenter study. J Clin Endocrinol Metab 99(5):1648\u20131655. https:\/\/doi.org\/10.1210\/jc.2013-4026 [published Online First: 2014\/02\/13]","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"282_CR35","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1210\/jc.2006-2388","volume":"92","author":"D El Fassi","year":"2007","unstructured":"El Fassi D, Nielsen CH, Bonnema SJ et al (2007) B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study. J Clin Endocrinol Metab 92(5):1769\u20131772. https:\/\/doi.org\/10.1210\/jc.2006-2388 [published Online First: 2007\/02\/08]","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"282_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1365-2249.2010.04191.x","volume":"161","author":"G Vannucchi","year":"2010","unstructured":"Vannucchi G, Campi I, Bonomi M et al (2010) Rituximab treatment in patients with active Graves\u2019 orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol 161(3):436\u2013443. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04191.x [published Online First: 2010\/06\/10]","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"282_CR37","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/art.22400","volume":"56","author":"K Vos","year":"2007","unstructured":"Vos K, Thurlings RM, Wijbrandts CA et al (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56(3):772\u2013778. https:\/\/doi.org\/10.1002\/art.22400 [published Online First: 2007\/03\/01]","journal-title":"Arthritis Rheum"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00282-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-021-00282-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00282-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T22:20:12Z","timestamp":1620685212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-021-00282-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1007\/s42000-021-00282-6","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"22 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All analyses were based on previously published studies; thus, no ethical approval was required.All analyses were based on previous published studies; thus, no informed consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}